Patient Preferences for Different Severities of and Treatments for Overactive Bladder

被引:29
|
作者
Wu, Jennifer M. [1 ]
Fulton, Rebekah G. [1 ]
Amundsen, Cindy L. [1 ]
Knight, Sharon K. [2 ,3 ]
Kuppermann, Miriam [2 ,3 ,4 ,5 ]
机构
[1] Duke Univ, Dept Obstet & Gynecol, Durham, NC 27707 USA
[2] Univ Calif San Francisco, Dept Obstet, Dept Gynecol, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Reprod Sci, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[5] Univ Calif San Francisco, Med Effect Res Ctr Diverse Populat, San Francisco, CA 94143 USA
来源
关键词
urge urinary incontinence; overactive bladder; utility; patient preferences; QUALITY-OF-LIFE; URINARY-INCONTINENCE; UTILITY SCORES; QUESTIONNAIRE; VALIDATION; MANAGEMENT; SYMPTOMS; OUTCOMES; COSTS;
D O I
10.1097/SPV.0b013e318223c8ad
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: Symptoms of overactive bladder (OAB) can have profound effects on women's quality of life. However, quantitative data on how women value these symptoms and their treatments are limited. We sought to assess women's preferences, which are referred to as utilities, for different severities of and treatment options for OAB. Methods: Eighty women-40 with OAB symptoms and 40 without OAB-were recruited from urogynecology and urology practices at an academic institution from April to November 2009. A single, trained interviewer administered a computerized preference elicitation tool to measure preferences for 4 OAB severity levels (urgency/frequency and mild, moderate, and severe urge incontinence), as well as 3 OAB treatments with and without adverse effects or complications, which included (1) anticholinergic medications, (2) botulinum toxin injection, and (3) sacral neuromodulation. Preferences were assessed using the time trade-off (TTO) method. Results: Median TTO scores for OAB decreased as severity increased (urgency/frequency, 0.88; mild, 0.92; moderate, 0.85; severe, 0.73). Median TTO scores assigned to anticholinergic medications were higher (0.93) than those for botulinum (0.88) and sacral neuromodulation (0.85), and adverse effects or complications lowered the utilities for each treatment (anticholinergics, 0.88; botulinum, 0.75; and sacral neuromodulation, 0.78). Conclusions: Women view symptoms of OAB, particularly moderate or severe symptoms, as being quite burdensome. The degree of invasiveness and the number of adverse effect/complications are important contributors to the utilities that women assign to the various treatment options.
引用
收藏
页码:184 / 189
页数:6
相关论文
共 50 条
  • [1] Patient preferences for treating refractory overactive bladder in the UK
    Hashim, Hashim
    Beusterien, Kathleen
    Bridges, John F. P.
    Amos, Kaitlan
    Cardozo, Linda
    [J]. INTERNATIONAL UROLOGY AND NEPHROLOGY, 2015, 47 (10) : 1619 - 1627
  • [2] Patient preferences for treating refractory overactive bladder in the UK
    Hashim Hashim
    Kathleen Beusterien
    John F. P. Bridges
    Kaitlan Amos
    Linda Cardozo
    [J]. International Urology and Nephrology, 2015, 47 : 1619 - 1627
  • [3] Durability of treatments for overactive bladder
    Dasgupta, P.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (05) : 528 - 529
  • [4] Determining patient preferences in the treatment of medication-refractory overactive bladder
    Speed, Jacqueline
    Welk, Blayne
    Comiter, Craig
    Elliott, Christopher
    [J]. NEUROUROLOGY AND URODYNAMICS, 2023, 42 (02) : 419 - 426
  • [5] Preferences for antimuscarinic therapy for overactive bladder
    Swinburn, Paul
    Lloyd, Andrew
    Ali, Shehzad
    Hashmi, Noreen
    Newal, David
    Najib, Hiba
    [J]. BJU INTERNATIONAL, 2011, 108 (06) : 868 - 873
  • [6] Treatments for overactive bladder: Focus on pharmacotherapy
    Geoffrion, Roxana
    [J]. JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2016, 38 (12) : S158 - S170
  • [7] Treatments for Overactive Bladder: Focus on Pharmacotherapy
    Geoffrion, Roxana
    Lovatsis, Danny
    Walter, Jens-Erik
    Chou, Queena
    Easton, William
    Epp, Annette
    Geoffrion, Roxana
    Harvey, Marie-Andree
    Larochelle, Annick
    Maslow, Kenny
    Neustaedter, Grace
    Pascali, Dante
    Pierce, Marianne
    Schulz, Jane A.
    Senikas, Vyta
    Wilkie, David
    [J]. JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2012, 34 (11) : 1092 - 1101
  • [8] Introduction: Overactive bladder and its treatments
    Abrams, P
    Wein, AJ
    [J]. UROLOGY, 2000, 55 (5A) : 1 - 2
  • [9] The recalcitrant overactive bladder patient
    Ghoniem, GM
    [J]. GERIATRICS, 2002, 57 : 23 - 29
  • [10] Overactive Bladder: the Patient Perspective
    Edmonds, Victoria S.
    Khan, Aqsa A.
    [J]. CURRENT BLADDER DYSFUNCTION REPORTS, 2024, 19 (01) : 89 - 94